Pyrophosphate, Fetuin A, IL1, IL6, TNFalpha, Control
Conditions
Keywords
Pyrophosphate
Brief summary
The investigator aim to identify the role of inorganic pyrophosphate and other anti-calcifying molecules in vascular disease in children with chronic kidney disease, with a view to developing therapeutic approaches aimed at limiting the onset of vasculopathy.
Detailed description
The study of pro- and anti-calcifying molecules in children with chronic kidney disease will be carried out using dosages made on serum in comparison with the dosage of these same molecules in control children matched according to age and sex. without chronic kidney disease. An evaluation of vascular function by clinical (auscultation, palpation) and ultrasound techniques (measurement of intima-media thickness and measurement of pulse wave velocity) will also be carried out in children with chronic kidney disease and compared to norms of children without chronic kidney disease. These evaluations aim to improve understanding of the pathophysiology of vascular calcification and thus open up therapeutic perspectives in these children.
Interventions
OTHERPPI and T50 dosing
Sampling for PPI determination and T50 in blood and urine.
Sponsors
Centre Hospitalier Universitaire de Nice
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
0 Years to 18 Years
Healthy volunteers
No
Inclusion criteria
All groups : * Minor patients (\<18 years) * Patients of both sexes * Informed patients and parents who have signed the informed consent form * Patients affiliated to social security Control group : \- Patients with no particular pathology undergoing surgery and receiving a preoperative check-up CKD groups : * Patients on dialysis for more than 3 months, regardless of technique * Kidney transplant patients * Patients with CKD, whatever the cause
Exclusion criteria
* Progressive cancer or kidney disease * Treatments that may modify PPi concentration (e.g. bisphosphonates)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Plasma pyrophosphate concentration [PPi]pl in children with CKD | 18 months | Compare plasma pyrophosphate concentration \[PPi\]pl between children with CKD (dialysis group and non-dialysis, non-transplant group) and \[PPi\]pl of children with normal renal function. Plasma PPi concentration during fasting sampling; (μmol/L) by a proprietary assay developed at LP2M. We will match the 3 MRC groups with their respective control groups according to age, sex and pubertal stage. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Plasma pyrophosphate [PPi]pl concentration in children with renal transplantation | 18 months | To compare the plasma pyrophosphate \[PPi\]pl concentration of children with renal transplantation with that of children with dialyzed CKD and children with normal renal function. Plasma PPi concentration during fasting sampling; (μmol/L) by a patented assay developed at LP2M. |
| Markers of phosphocalcic metabolism | 18 months | To investigate an association between plasma PPi concentration and markers of phosphocalcium metabolism in patients in the 3 MRC groups: dialysis, transplant and non-dialysis/non-transplant). The T50 (Serum protection against vascular calcification) marker of phosphocalcium metabolism will be studied. |
| Urinary PPi concentration | 18 months | To search for an association between urinary Ppi concentration and markers of phosphocalcium metabolism in patients in the 3 MRC groups: dialysis, transplant and non-dialysis/non-transplant). Urinary PPi concentration will be measured by a patented assay developed at LP2M. |
| Markers of vascular damage in CKD | 18 months | To look for an association between blood and urine Ppi concentrations and markers of vascular damage in MRC in each of the 3 MRC groups. The following markers of vascular damage in CKD will be studied: * Measurement of aortic stiffness by ultrasound aortic pulse wave velocity * Measurement of carotid intima-media thickness by ultrasound |
Countries
France
Contacts
CONTACTJulie BERNARDOR
Outcome results
None listed